AEON BIOPHARMA INC

AEON Biopharma insider purchase: CEO Timothy Lynch buys 1.15 M shares at $0.21 amid a 74% yearly decline and high social‑media buzz, signaling renewed confidence and potential catalysts.

Insider buying at AEON Biopharma signals confidence in its neurotoxin pipeline, hinting at future upside and urging investors to watch clinical milestones.

AEON Biopharma CEO’s 3 M RSU purchase signals long‑term confidence amid volatile stock, showing how executive alignment can stabilize shares.